Skip to main content

Champions Oncology to Announce Third Quarter Financial Results on Tuesday, March 15, 2022

HACKENSACK, NJ / ACCESSWIRE / March 11, 2022 / Champions Oncology, Inc. (CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, will report its financial and operational results for the third quarter ended January 31, 2022, on Tuesday, March 15, 2022, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EDT (1:30 P.M. PDT). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 692343. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 44896, or by accessing the investors section of the company's website within 72 hours.

About Champions Oncology, Inc.

Champions Oncology is a data-driven research organization, with headquarters in the United States, that develops innovative therapeutics against cancer targets, offers groundbreaking research software as a service, and provides end-to-end R&D services to biopharma organizations. Champions Oncology is actively engaged in the transformation of drug discovery through a novel approach of pharmaco-pheno-multiomic integration.

For more information, please visit www.ChampionsOncology.com.

SOURCE: Champions Oncology, Inc.



View source version on accesswire.com:
https://www.accesswire.com/692638/Champions-Oncology-to-Announce-Third-Quarter-Financial-Results-on-Tuesday-March-15-2022

Recent Quotes

View More
Symbol Price Change (%)
AMZN  221.57
+5.09 (2.35%)
AAPL  263.60
+1.36 (0.52%)
AMD  234.72
-5.84 (-2.43%)
BAC  51.98
-0.06 (-0.12%)
GOOG  252.98
-4.04 (-1.57%)
META  732.98
+0.81 (0.11%)
MSFT  515.50
-1.29 (-0.25%)
NVDA  180.28
-2.36 (-1.29%)
ORCL  277.40
+0.22 (0.08%)
TSLA  445.15
-2.28 (-0.51%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.